Robotic surgery gets a sense of touch: can it make prostate cancer operations safer?
NCT ID NCT07247175
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new feature on the da Vinci 5 surgical robot that gives surgeons a sense of touch during prostate cancer surgery. 60 patients will take part, with surgeons randomly using the force feedback on or off. The goal is to see if this helps surgeons learn faster and reduces tissue damage.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- da Vinci 5 robotic system with force feedback
- What this could lead to
- If successful, this could show that force feedback makes robotic surgery safer and easier to learn, potentially improving outcomes for prostate cancer patients.
- What could go wrong
- This is a small, early-phase study with only 60 patients at one center. The benefits seen may not apply to all surgeons or hospitals, and the force feedback may not significantly improve safety or learning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male patients aged ≥19 years. Histologically confirmed localized prostate cancer, clinical stage T1-T3a, N0, M0. Scheduled to undergo robot-assisted radical prostatectomy (RARP) at Samsung Medical Center. No radiologic evidence of distant metastasis, and disease deemed surgically resectable via robotic approach. Medically fit for general anesthesia and laparoscopic surgery, classified as ASA physical status I-III. Baseline erectile function preserved, defined as IIEF-5 ≥12 within 6 months prior to surgery. Provided written informed consent for participation after full explanation of the study. Exclusion Criteria: * Locally advanced or metastatic prostate cancer (clinical stage ≥T3b, N1, or M1\*\*). Prostate volume ≥60 cc on preoperative MRI, which may complicate robotic dissection standardization. History of pelvic radiotherapy for any malignancy. Previous androgen deprivation therapy (ADT) or other hormonal therapy for prostate cancer. History of prior prostate surgery, such as TURP or HoLEP. History of spinal cord injury or major pelvic surgery that may alter pelvic anatomy. Medical contraindications to robotic/laparoscopic surgery or general anesthesia (e.g., severe cardiopulmonary disease, ASA ≥ IV). Anatomic limitations (e.g., extreme obesity or deformity) precluding safe robotic access. Device or software malfunction preventing proper activation or deactivation of the Force Feedback system. Any other condition deemed inappropriate for study participation by the principal investigator (e.g., cognitive impairment affecting consent or follow-up).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinically localized prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSoeul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?